Author： Brown Peter D.
Publisher： Springer Publishing Company
ISSN： 0969-6970
Source： Angiogenesis, Vol.1, Iss.2, 1998-01, pp. : 142-154
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Matrix metalloproteinases (MMPs) are a family of structurally related enzymes that are capable of degrading a wide variety of extracellular matrix proteins. In addition to the role played by these enzymes in normal tissue remodeling, MMPs have been implicted in the pathogenesis of diseases such as rheumatoid arthritis and multiple sclerosis. In cancer increased MMP activity may facilitate tumor invasion, metastasis and tumor angiogenesis. Expression of high levels of MMPs in certain malignancies has been shown to be associated with a poor prognosis. Using structure-based design, a range of low molecular weight synthetic MMP inhibitors have been developed. These have proven effective in animal models of disease and several (CGS 27023A, AG3340, Ro 32-3555 and marimastat) have now commenced clinical trials.
Related content
By Gao Fei Chen Xin-Lei Wei Peng Gao Hong-Juan Liu Yi-Xun
Endocrine Journal, Vol. 16, Iss. 1, 2001-10 ,pp. :
Access to resources
Recommend
By Bogusiewicz Michał Stryjecka-Zimmer Marta Postawski Krzysztof Jakimiuk Artur Rechberger Tomasz
Gynecological Endocrinology, Vol. 23, Iss. 9, 2007-09 ,pp. :
By Naruse Katsuhiko Lash Gendie E. Innes Barbara A. Otun Harry A. Searle Roger F. Robson Stephen C. Bulmer Judith N.
Human Reproduction, Vol. 24, Iss. 3, 2009-03 ,pp. :
By Pedersen Susanne Hetland Merete Sørensen Inge Østergaard Mikkel Nielsen Hans Johansen Julia
Clinical Rheumatology, Vol. 29, Iss. 11, 2010-11 ,pp. :